Arcadia Biosciences Stock Performance
| RKDA Stock | USD 3.15 0.15 4.55% |
The firm shows a Beta (market volatility) of 0.98, which signifies possible diversification benefits within a given portfolio. Arcadia Biosciences returns are very sensitive to returns on the market. As the market goes up or down, Arcadia Biosciences is expected to follow. At this point, Arcadia Biosciences has a negative expected return of -0.98%. Please make sure to confirm Arcadia Biosciences' skewness, day typical price, and the relationship between the maximum drawdown and daily balance of power , to decide if Arcadia Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Arcadia Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's fundamental indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (4.55) | Five Day Return (4.55) | Year To Date Return (48.28) | Ten Year Return (99.95) | All Time Return (99.95) |
Last Split Factor 1:40 | Dividend Date 2018-01-24 | Last Split Date 2023-03-01 |
1 | Acquisition by Bolles Albert D. of 9137 shares of Arcadia Biosciences at 3.69 subject to Rule 16b-3 | 12/23/2024 |
2 | Acquisition by Reiter Sarah of 700 shares of Arcadia Biosciences at 1.72 subject to Rule 16b-3 | 01/08/2025 |
3 | Acquisition by Thomas Schaefer of 700 shares of Arcadia Biosciences at 2.49 subject to Rule 16b-3 | 02/03/2025 |
4 | RKDA Stock Alert Halper Sadeh LLC Is Investigating Whether the Merger of Arcadia Biosciences, Inc. is Fair to Shareholders | 02/25/2025 |
5 | Disposition of tradable shares by Mark Kawakami of Arcadia Biosciences subject to Rule 16b-3 | 02/27/2025 |
6 | Acquisition by Comcowich Kevin of 5000 shares of Arcadia Biosciences at 5.8776 subject to Rule 16b-3 | 03/05/2025 |
7 | Arcadia Biosciences Announces Date of Fourth Quarter 2024 Financial Results and Business Highlights Conference Call | 03/06/2025 |
8 | Arcadia Biosciences Inc Q4 2024 Earnings Report Preview What To Look For | 03/21/2025 |
| Begin Period Cash Flow | 20.6 M |
Arcadia |
Arcadia Biosciences Relative Risk vs. Return Landscape
If you would invest 609.00 in Arcadia Biosciences on December 22, 2024 and sell it today you would lose (294.00) from holding Arcadia Biosciences or give up 48.28% of portfolio value over 90 days. Arcadia Biosciences is currently does not generate positive expected returns and assumes 4.2018% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Arcadia, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Arcadia Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Arcadia Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Arcadia Biosciences, and traders can use it to determine the average amount a Arcadia Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2337
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RKDA |
Estimated Market Risk
| 4.2 actual daily | 37 63% of assets are more volatile |
Expected Return
| -0.98 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.23 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Arcadia Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Arcadia Biosciences by adding Arcadia Biosciences to a well-diversified portfolio.
Arcadia Biosciences Fundamentals Growth
Arcadia Stock prices reflect investors' perceptions of the future prospects and financial health of Arcadia Biosciences, and Arcadia Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Arcadia Stock performance.
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.45 | ||||
| Profit Margin | (1.06) % | ||||
| Operating Margin | (1.15) % | ||||
| Current Valuation | (1.9 M) | ||||
| Shares Outstanding | 1.36 M | ||||
| Price To Earning | 4.84 X | ||||
| Price To Book | 0.42 X | ||||
| Price To Sales | 0.82 X | ||||
| Revenue | 5.33 M | ||||
| Gross Profit | 1.11 M | ||||
| EBITDA | (13.58 M) | ||||
| Net Income | (13.99 M) | ||||
| Cash And Equivalents | 21.23 M | ||||
| Cash Per Share | 0.96 X | ||||
| Total Debt | 1.01 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 6.34 X | ||||
| Book Value Per Share | 7.54 X | ||||
| Cash Flow From Operations | (15.29 M) | ||||
| Earnings Per Share | (6.77) X | ||||
| Market Capitalization | 4.47 M | ||||
| Total Asset | 19.7 M | ||||
| Retained Earnings | (271.84 M) | ||||
| Working Capital | 11.38 M | ||||
| Current Asset | 52.02 M | ||||
| Current Liabilities | 3.45 M | ||||
About Arcadia Biosciences Performance
By analyzing Arcadia Biosciences' fundamental ratios, stakeholders can gain valuable insights into Arcadia Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Arcadia Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Arcadia Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 194.91 | 187.08 | |
| Return On Tangible Assets | (0.64) | (0.67) | |
| Return On Capital Employed | (0.99) | (1.04) | |
| Return On Assets | (0.64) | (0.67) | |
| Return On Equity | (1.25) | (1.19) |
Things to note about Arcadia Biosciences performance evaluation
Checking the ongoing alerts about Arcadia Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Arcadia Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Arcadia Biosciences generated a negative expected return over the last 90 days | |
| Arcadia Biosciences has high historical volatility and very poor performance | |
| Arcadia Biosciences has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 5.33 M. Net Loss for the year was (13.99 M) with profit before overhead, payroll, taxes, and interest of 1.11 M. | |
| Arcadia Biosciences currently holds about 21.23 M in cash with (15.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.96. | |
| Latest headline from gurufocus.com: Arcadia Biosciences Inc Q4 2024 Earnings Report Preview What To Look For |
- Analyzing Arcadia Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Arcadia Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Arcadia Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Arcadia Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Arcadia Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Arcadia Biosciences' stock. These opinions can provide insight into Arcadia Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Arcadia Stock analysis
When running Arcadia Biosciences' price analysis, check to measure Arcadia Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcadia Biosciences is operating at the current time. Most of Arcadia Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcadia Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcadia Biosciences' price. Additionally, you may evaluate how the addition of Arcadia Biosciences to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |